Join us for the 9th Annual Updates in the Treatment and Management of Hematologic Malignancies Highlights from Orlando

Thursday February 6, 2020 | 5:30pm – 9:00 pm

Colorado Blood Cancer Institute and Sarah Cannon Cancer Insitute at Presbyteriona/St. Luke's Medical Center


Registration

To register for this event or for additional information, please contact Lisa Dowd. Registration is limited to Physicians and Advance Practice Providers.

(720) 754-4836

Email


Location

Empower Field at Mile High
(formerly Sports Authority Field at Mile High)

1701 Bryant Street
Denver, CO 80204

Maps & Directions

Agenda


5:30 - 9:00 pm

Registration and Dinner Begin at 5:30 pm

Education Session Begins at 6:00 pm

Welcome and Introduction

Jeffrey V. Matous, MD

Colorado Blood Cancer Institute


Indolent Lymphoma and CLL

Danielle Brander, MD

Director, CLL & Lymphoma Clinical Research Program
Duke University


Hodgkin Lymphoma and Aggressive NHL

Joseph M. Connors, MD, FRCPC

Clinical Professor Emeritus
BC Cancer Center for Lymphoid Cancer


Leukemia

Harry P. Erba, MD, PhD

Director, Leukemia Program
Duke University


Multiple Myeloma

Angela Dispenzieri, MD

Research Chair, Division of Hematology
Mayo Clinic


Speakers


Joseph M Connors, MD, FRCPC

Clinical Professor Emeritus
Department of Medicine, University of British Columbia
Clinical Director, BC Cancer Centre for Lymphoid Cancer 1989-2018

Dr. Connors is best known for his clinical investigations into the treatment of Hodgkin lymphoma, non-Hodgkin lymphoma, the chronic lymphocytic leukemias and multiple myeloma. He was the BC Cancer Lymphoma Tumor Group Chair from 1987 to 2007 and Clinical Director of the BC Cancer Centre for Lymphoid Cancer from 1989 to 2018. He has published more than 400 peer-reviewed articles focused on lymphoid cancer, which have been cited more than 70,000 times in the medical literature.


Danielle Brander, MD

Assistant Professor, Medicine
Director, CLL & Lymphoma Clinical Research Program
Duke University
Durham, NC

Cellular Therapy & Hematologic Malignancies Specialist Danielle Brander, MD is a graduate of Duke University School of Medicine, where she completed her residency in the Department of Internal Medicine. Dr. Brander completed her fellowship at Duke University in the Department of Internal Medicine and trained in Hematology/Oncology. Her main focus is on Chronic Lymphocytic Leukemia and other slow growing or indolent Lymphomas. She is focused on individualized patient care and is passionate about learning in an ever-changing field. Dr. Brander has been practicing at Duke University in the Division of Hematologic Malignancies and Cellular Therapy since 2013. Dr. Brander holds certificates from the American Board of Internal Medicine for Internal Medicine, Hematology and Medical Oncology. In 2016, Dr. Brander was awarded the William Kane Hematology/Oncology Junior Faculty teaching award. Dr. Brander is a member of several professional and scientific societies.


Angela Dispenzieri, MD

Professor, Medicine, Laboratory Medicine
Research Chair, Division of Hematology
Mayo Clinic
Rochester, MN

Dr. Dispenzieri was born in New York City, received her Bachelor of Science from Massachusetts Institute of Technology in Cambridge, MA, and earned her medical degree from Albert Einstein College of Medicine in New York. She completed an Internal Medicine residency and Hematology/Oncology fellowship at the Mayo Graduate School of Medicine in Rochester, Minnesota. She has been an author or co-author on over six hundred manuscripts and book chapters in the field of plasma cell disorders, including multiple myeloma, immunoglobulin light chain amyloidosis, POEMS syndrome, Castleman Disease, and mass spectrometry techniques. She is immediate past-president of the International Society of Amyloidosis.


Harry P. Erba, MD, PhD

Professor, Medicine
Director, Leukemia Program
Duke University
Durham, NC

Dr. Erba received a bachelor’s degree in biology from Yale University and his medical degree and doctorate in biophysics from Stanford University. He did his internship and residency in internal medicine at the Brigham and Women's Hospital, Harvard Medical School. Following a fellowship in hematology/oncology at the same institution, he joined the Harvard Medical School faculty for 3 years. He then moved to the University of Michigan at Ann Arbor in 1996, where he rose to the academic rank of Associate Professor of Internal Medicine. He moved to the University of Alabama at Birmingham (UAB) in 2012 as Professor of Internal Medicine. He served as the Director of the Hematologic Malignancy Program in the Division of Hematology/Oncology and as the Associate Director for Clinical Research in the UAB Comprehensive Cancer Center. He moved to Duke University as Professor of Medicine on July 1, 2018 and is a faculty member of the Division of Hematologic Malignancy and Cellular Therapy. He serves as the Director of the Leukemia Program as well as Director of Phase I Unit for Hematologic Malignancies. In October 2012, he was appointed Chairman of the SWOG Leukemia Committee and now serves on the NCI Leukemia Steering Committee. Dr. Erba served on the National Comprehensive Cancer Network (NCCN) Practice Guidelines Committees for acute myeloid leukemia, chronic myeloid leukemia, myelodysplastic syndromes and myeloid growth factors, until 2010. He has been an active clinical investigator in acute myeloid leukemia, myelodysplastic syndrome, myeloproliferative neoplasms and both acute and chronic lymphocytic leukemia.


Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of HealthONE and Colorado Pain Society. HealthONE is accredited by the ACCME to provide continuing medical education for physicians.

Credit:

HealthONE CME designates this live activity for a maximum of 3 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure:

HealthONE is committed to providing CME that is balanced, objective, and evidenced-based. In accordance with the Accreditation Council for Continuing Medical Education Essentials and Standards, all parties involved in content development are required to disclose any relevant conflicts of interest (i.e. any entity producing, marketing, re-selling, or distributing health care goods or services consumed by or used on patients) relating to the topics of this education activity. HealthONE has established mechanisms to resolve conflicts of interest should they arise. The course director, speakers and members of the planning committee have nothing to disclose.

Commercial Support:

The series was developed without support from any commercial interests. A commercial interest is defined as any entity producing, marketing, re-selling, or distributing healthcare goods or services consumed by, or used on, patients. Note: The ACCME does not consider providers of clinical service directly to patients to be commercial interests - unless the provider of clinical services is owned, or controlled by, an ACCME-defined commercial interest.

Core Competencies:

This activity has been developed with consideration given to the ACGME/ABMS Competencies, Institute of Medicine Core Competencies, and/or Interprofessional Education Collaborative Competencies. This activity will increase your competency in the areas of: patient care and procedural skills, medical knowledge, practice-based learning and improvement, interpersonal and communication skills, provide patient-centered care, working in interdisciplinary teams, employ evidence-based practice, apply quality improvement, values/ethics for interprofessional practice, roles/responsibilities, interprofessional communication, and teams and teamwork.